JP2024530170A5 - - Google Patents
Info
- Publication number
- JP2024530170A5 JP2024530170A5 JP2024506733A JP2024506733A JP2024530170A5 JP 2024530170 A5 JP2024530170 A5 JP 2024530170A5 JP 2024506733 A JP2024506733 A JP 2024506733A JP 2024506733 A JP2024506733 A JP 2024506733A JP 2024530170 A5 JP2024530170 A5 JP 2024530170A5
- Authority
- JP
- Japan
- Prior art keywords
- identity
- sequence
- sequence number
- bacteriophage
- polynucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163228504P | 2021-08-02 | 2021-08-02 | |
| US63/228,504 | 2021-08-02 | ||
| PCT/US2022/074446 WO2023015195A1 (en) | 2021-08-02 | 2022-08-02 | Bacteriophages with improved antimicrobial activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024530170A JP2024530170A (ja) | 2024-08-16 |
| JP2024530170A5 true JP2024530170A5 (cg-RX-API-DMAC7.html) | 2025-08-13 |
Family
ID=85156425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506733A Pending JP2024530170A (ja) | 2021-08-02 | 2022-08-02 | 改善された抗微生物活性を有するバクテリオファージ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240352428A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4380586A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024530170A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240042484A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118591383A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022323171A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3227846A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310549A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023015195A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025143108A1 (ja) | 2023-12-27 | 2025-07-03 | 株式会社Arrowsmith | 緑膿菌バクテリオファージ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0300597D0 (en) * | 2003-01-10 | 2003-02-12 | Microbiological Res Authority | Phage biofilms |
| WO2011044279A2 (en) * | 2009-10-06 | 2011-04-14 | Bio Architecture Lab, Inc. | Microbial systems for producing commodity chemicals |
| AU2015362618B2 (en) * | 2014-12-16 | 2022-01-27 | C3J Therapeutics, Inc. | Compositions of and methods for in vitro viral genome engineering |
| WO2020254523A1 (en) * | 2019-06-18 | 2020-12-24 | Eligo Bioscience | Bacterial delivery vehicles comprising tracer nucleic acid sequences |
-
2022
- 2022-08-02 EP EP22854066.2A patent/EP4380586A4/en active Pending
- 2022-08-02 AU AU2022323171A patent/AU2022323171A1/en active Pending
- 2022-08-02 JP JP2024506733A patent/JP2024530170A/ja active Pending
- 2022-08-02 CN CN202280065190.8A patent/CN118591383A/zh active Pending
- 2022-08-02 IL IL310549A patent/IL310549A/en unknown
- 2022-08-02 CA CA3227846A patent/CA3227846A1/en active Pending
- 2022-08-02 KR KR1020247007051A patent/KR20240042484A/ko active Pending
- 2022-08-02 WO PCT/US2022/074446 patent/WO2023015195A1/en not_active Ceased
- 2022-08-02 US US18/294,138 patent/US20240352428A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Łusiak-Szelachowska et al. | Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far | |
| Pereira et al. | Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B | |
| JP2023523319A5 (cg-RX-API-DMAC7.html) | ||
| US7758856B2 (en) | Bacteriophage for the treatment of bacterial biofilms | |
| Letkiewicz et al. | The perspectives of the application of phage therapy in chronic bacterial prostatitis | |
| JP7449967B2 (ja) | 療法バクテリオファージ組成物 | |
| CN112218659A (zh) | 用于治疗葡萄球菌感染的治疗性噬菌体组合物 | |
| Hong et al. | Optimizing in vitro phage-ciprofloxacin combination formulation for respiratory therapy of multi-drug resistant Pseudomonas aeruginosa infections | |
| US20210187046A1 (en) | Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof | |
| CN116018154A (zh) | 用于治疗假单胞菌属感染的噬菌体组合物 | |
| US20210361727A1 (en) | Bacteriophage compositions for treating pseudomonas infections | |
| ES2594901T3 (es) | Composición farmacéutica para el tratamiento de una enfermedad de las vías respiratorias | |
| Selim et al. | Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens | |
| JP2020524172A5 (cg-RX-API-DMAC7.html) | ||
| JP2015524461A (ja) | 環状骨格ペプチドとの組合せ | |
| Grygorcewicz et al. | Bacteriophage‐based approach for treatment of urinary tract infections: a quick outlook | |
| Gawad et al. | Effect of EDTA on biofilm formation and antibiotic susceptibility of multidrug resistant uropathogenic Escherichia coli clinical isolates in Egypt | |
| Gonzalez‐Moreno et al. | Bacteriophages for Treatment of Biofilm Infections | |
| Karvouniaris et al. | Inhaled antibiotics for nosocomial pneumonia | |
| Reyes et al. | Current perspectives: therapeutic uses of tobramycin | |
| CN108498519A (zh) | 一种抗感染组合物、制剂及其应用 | |
| Babita et al. | Phage therapy reimagined: viral | |
| Nachimuthu et al. | Reviving Phage Therapy: A Novel Approach to Treat Respiratory-Associated Infections | |
| JP7811652B2 (ja) | リボース及びアミノ酸を含む医薬組成物 | |
| JP2023513934A5 (cg-RX-API-DMAC7.html) |